Oncology

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.

Socioeconomic barriers and medical distrust hindered COVID-19 vaccine completion among cancer survivors, a high-risk group for severe outcomes from the virus, according to a recent study.

Over the past 45 years, cancer prevention and screening interventions have averted nearly 6 million deaths from major cancers in the United States, according to new research.

Emerging data highlights a critical complication for patients with metastatic lung cancer undergoing treatment with immune checkpoint inhibitors (ICIs), including PD-1 and PD-L1 blockers.